MRD negativity as a treatment endpoint in CLL
Measurable residual disease (MRD) negativity is an important treatment endpoint for many hematological malignancies and has the potential to be used to inform therapy cessation decision making. Here, ...
Author: VJHemOnc
Added: 08/07/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Hematology